RISK FACTOR PREVALENCE AND PROBABILITY OF FATAL CARDIOVASCULAR EVENTS IN MEN 42-44 YEARS OLD

Aim. To evaluate  prevalence  of the  main risk factors  (RF) and  fatal outcome probability of cardiovascular diseases (CVD) in 10 years among men 42-44 years old.

Material and methods. Totally, 303 men studied at the age 42-44 y.o., under  the  ordinary step  of 32-year  lasting prospective  cohort  study. Response on invitation for investigation was 30,1%. Subjects underwent standardized   questionnaire;  triple blood  pressure  measurement, as pulse, length and mass of body; thickness of adipose layers over triceps, scapula and abdominal wall measurement; waist and hip circumference; measurement of total and  high density  lipoproteides  cholesterol,  as triglycerides and blood glucose.  Statistics was done via software IBM SPSS Statistics 22.

Results. The characteristics of the studied group is presented as simple descriptive statistics. At the moment of study, 23% of men had elevated blood pressure, mostly at the level of arterial hypertension (AH) grade 1 (14,5%). There was anamnesis  of AH in 44,6% participants  and 27,1% take antihypertensive medication, but just 8,9% do treat actively. Overweight and obesity were found in 67% of the studied.  Abdominal obesity was found in 87 (28,7%). More than 40% of them smoke. In 42,6% of men there  were significant proatherogenic changes  in serum found.

Low physical activity was set for 26,1% of the studied. 65% of men from this group have 2 and more risk factors. It is stated that most of the men (90%) have moderate  risk of fatal CVD development next 10 years,  by SCORE, and just 8,9% have low estimated  risk. The main impact on the overall risk have cholesterol (47,6%) and smoking (33,7%).

Conclusion. High rate of the main RF for CVD in men 42-44 y.o. and moderate probability of fatal CVD for the next 10 years strictly dictate on the necessity  of individualized active prevention of CVD with the main direction towards positive motivation for healthy life style — cessation of bad  habits,  especially smoking, rational food intake, physical activity optimization,  atherogenic   lipid profile  correction  and  effective  AH treatment.

1. Oganov RG, Kontsevaya AV, Kalinina AM. Economic burden of cardiovascular disease in the Russian Federation. Cardiovascular Therapy and Prevention 2011; 10 (4): 4–9. Russian (Оганов Р.Г., Концевая А.В., Калинина А.М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации // Кардиоваскулярная терапия и профилактика 2011; 10 (4): 4–9).

2. Boytsov SA. Prevalence of cardiovascular risk factors and cardiovascular prevention quality in primary healthcare in Russia and European countries: EURIKA Study results. Cardiovascular Therapy and Prevention 2012; 11 (1): 11–16. Russian (Бойцов С.А. Структура факторов сердечно-сосудистого риска и качество мер их профилактики в первичном звене здравоохранения в России и в Европейских странах (по результатам исследования EURIKA) // Кардиоваскулярная терапия и профилактика 2012; 11 (1): 11–16).

3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937-52.

4. WHO. Global health risks: Mortality and burden of disease attributable to selected major risks. Nonserial Publication. Geneva: World Health Organization, 2009, 68 pages. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&codcch=772 [accessed 23 April 2016].

5. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age. Ann Intern Med 2001; 134(6): 433–39.

6. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388–98.

7. Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med 2004; 117: 219-27.

8. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Russ J Cardiol 2014; 1 (105): 7-94. Russian (Рабочая группа по лечению артериальной гипертонии Европейского Общества Гипертонии (European Society of Hypertension, ESH) и Европейского Общества Кардиологов (European Society of Cardiology, ESC). 2013 ESH/ESC Рекомендации по лечению артериальной гипертензии. Российский кардиологический журнал 2014; 1(105): 7-94.)

9. WHO. Waist Circumference and Waist–Hip Ratio: Report of a WHO Expert Consultation (Geneva, 8–11 December 2008). Geneva: World Health Organization, 2011, 39 pages. Available from: http://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en/ [accessed 23 April 2016].

10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.

11. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35(8): 1381-95.

12. Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ) – Short and Long Forms - 2005. Available from: http://www.ipaq.ki.se/ [accessed 23 April 2016].

13. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M. et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

14. Boytsov SA, Balanova YA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM, Duplyakov DV, Efanov AY, Zhernakova YV, Konradi AO, Libis RA, Minakov AV, Nedogoda SV, Oshchepkova EV, Romanchuk SA, Rotar OP, Trubacheva IA, Chazova IE, Shlyakhto EV. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By data from ECCD. Cardiovascular Therapy and Prevention 2014; 13(4): 4–14. Russian (Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Конради А.О., Либис Р.А., Минаков А.В., Недогода С.В., Ощепкова Е.В., Романчук С.А., Ротарь О.П., Трубачева И.А., Чазова И.Е., Шляхто Е.В. Артериальная гипертония среди лиц 25—64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014; 13(4): 4–14.)

15. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015; 131(4): e29-322.

16. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22 (1): 11–9.

17. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288(14): 1723–27.

18. European Society of Cardiology. The shape of things to come: study predicts increase in adult obesity prevalence in almost all European countries by 2030. May 09, 2014. Available from: http://www.escardio.org/ [accessed 26 April 2016]

19. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-78.

20. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A Potential Decline in Life Expectancy in the United States in the 21st Century. N Engl J Med 2005; 352: 1138-45.

21. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis categories. JAMA 2013; 309(1): 71-82.

22. Balanova YA, Shalnova SA, Deev AD, Kapustina AV, Konstantinov VV, Boytsov SA. The prevalence of smoking in Russia. What has changed in 20 years? Profilakticheskaia meditsina 2015; 18(6): 47-52. Russian (Баланова Ю.А., Шальнова С.А., Деев А.Д., Капустина А.В., Константинов В.В., Бойцов С.А. Распространенность курения в России. Что изменилось за 20 лет? Профилактическая медицина 2015; 18(6): 47-52.)

23. Agaku IT, King BA, Dube SR. Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults - United States, 2005-2012. MMWR Morb Mortal Wkly Rep 2014; 63(2): 29-34.

24. Zatoński W, Przewoźniak K, Sulkowska U, West R, Wojtyła A. Tobacco smoking in countries of the European Union. Ann Agric Environ Med 2012; 19(2): 181-92.

25. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290(7): 898-904.

26. Achenbach S, Moselewski F, Ropers D, Ferencic M, Hoffmann U, Mac Neill B, Pohle K, Baum U, Anders K, Jang Ik-K, Daniel WG, Brady TJ. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation 2004; 109(1): 14-7.

27. Metelskaya VA, Shalnova SA, Deev AD, Gomyranova NV, Litinskaya OA, Evstifeeva SE, Boytsov SA. Analysis of the prevalence of the indicators characterizing atherogenicity lipoprotein spectrum, residents of the Russian Federation. By data from ECCD. Profilakticheskaia meditsina 2016; 19(1): 15-23. Russian (Метельская В.А., Шальнова С.А., Деев А.Д., Гомыранова Н.В., Литинская О.А., Евстифеева С.Е., Бойцов С.А. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина 2016; 19(1): 15-23.)

28. Centers for Disease Control and Prevention (CDC). Prevalence of cholesterol screening and high blood cholesterol among adults—United States, 2005, 2007, and 2009. MMWR Morb Mortal Wkly Rep 2012; 61: 697-702.

29. WHO. Global Health Observatory (GHO) data. Raised cholesterol: Situation and trends. Available from: http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/ [accessed 23 April 2016].

30. Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamonova GV, Gatagonova TM, Duplyakov DV, Efanov AY, Zhernakova YV, Il’in VA, Konradi AO, Libis RA, Minakov EhV, Nedogoda SV, Oschepkova EV, Romanchuk SV, Rotar OP, Trubacheva IA, Deev AD, Shalnova SA, Chazova IE, Shlyakhto EV, Boytsov SA. The prevalence of risk factors for noncommunicable diseases in the Russian population in 2012-2013. Results of the study ECCD. Cardiovascular Therapy and Prevention 2014; 13(6): 4-11. Russian (Муромцева Г.А., Концевая А.В. Константинов В.В., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Ильин В.А., Конради А.О., Либис Р.А., Минаков Э.В, Недогода С.В., Ощепкова Е.В, Романчук С.В, Ротарь О.П., Трубачева И.А., Деев А.Д., Шальнова С.А., Чазова И.Е., Шляхто Е.В., Бойцов С.А. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ // Кардиоваскулярная терапия и профилактика 2014; 13(6): 4-11.)

31. WHO. Prevalence of insufficient physical activity, age 15+, age-standardized: both sexes. Geneva: World Health Organization, 2010. Available from: http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/physical_inactivity/atlas.html [accessed 23 April 2016].

32. Bauman A, Bull F, Chey T, Craig CL, Ainsworth BE, Sallis JF, Bowles HR, Hagstromer M, Sjostrom M, Pratt M; IPS Group. The International Prevalence Study on Physical Activity: results from 20 countries // Int J Behav Nutr Phys Act 2009; 6: 21.

33. Physical activity strategy for the WHO European Region 2016–2025. Regional Committee for Europe. 65th session (Vilnius, Lithuania, 14–17 September 2015). Copenhagen: WHO Regional Office for Europe, 2015, 33 pages. Russian Available from: http://www.euro.who.int/en/about-us/governance/regional-committee-for-europe/65th-session/documentation/working-documents [accessed 23 April 2016] (Стратегия в области физической активности для Европейского региона ВОЗ, 2016–2025 гг. Европейский региональный комитет. Шестьдесят пятая сессия (Вильнюс, Литва, 14–17 сентября 2015 г.). Копенгаген: Европейское региональное бюро ВОЗ, 2015.)

34. Myers J. Exersise and cardiovascular health // Circulation 2003; 107: e2-e4.

35. Lindman AS, Selmer R, Tverdal A, Pedersen JI, Eggen AE, Veierød MB. The SCORE risk model applied to recent population surveys in Norway compared to observed mortality in the general population // Eur J Cardiovasc Prev Rehabil 2006; 13(5): 731-7.